ImmuCell (ICCC) Q2 FY26 earnings call

ImmuCell delivered strong commercial growth in Q2 FY26, driven by increased domestic sales and distributor volumes, alongside significant market share gains for its First Defense product. The company is actively investing in a major capacity expansion program for its colostrum processing, leveraging former Re-Tain facilities, while managing gross margin pressures from manufacturing output and cost shifts. An investigational study for Re-Tain is ongoing, with results expected by end of September or early October.